Hydroxychloroquine & COVID 19: Is It a Clinical "Bear Market" for the Drug?
JUN 05, 2020 | CONTAGION® EDITORIAL STAFF
Segment Description: Jason Pogue, PharmD, BCPS, BCIDP, clinical pharmacist and professor in infectious diseases at the University of Michigan College of Pharmacy, speaks with Contagion about the emerging picture for hydroxychloroquine, a now-controversial drug which made headlines after showing promise in the lab against SARS-CoV-2.
The debate has been complicated in recent days, after The New England Journal of Medicine and The Lancet had authors issue retractions of articles based on a potentially faulty data source. The contested articles came from a database which cannot be verified. The results also showed what some view as an unrealistic level of harm from the drug, even among hydroxychloroquine skeptics.
A different publication, on use of the drug for out-patient prophylaxis, has offered less contested insight.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512